Anavex stock crashes after pulling Alzheimer's drug application in EU

Anavex Life Sciences faced a sharp decline in its stock value after withdrawing its EU marketing application for blarcamesine, an Alzheimer's treatment. The European Medicines Agency (EMA) had already signalled it would not approve the drug, raising concerns about its future viability. Investors reacted swiftly, sending shares to a 52-week low on March 25, 2026. The company's decision to pull its application followed the EMA's criticism of the current data package. Regulators suggested additional clinical trials or complex analyses might be necessary before reconsideration. This setback delays Anavex's commercialisation plans and casts doubt on the drug's path to market.

Earlier Phase 2b/3 results had shown promise, with blarcamesine delivering a 36% improvement in Alzheimer's symptoms and a reduction in brain atrophy. Despite this, the EMA's rejection often hints at similar challenges with the U.S. Food and Drug Administration (FDA), complicating global approval prospects. The stock crash saw AVXL shares plummet by 18% pre-market to $3.43 and 35% intraday to €2.33 on March 25. A slight recovery to €2.48 (+5.90%) followed the next day, but the damage remained severe. The stock now sits nearly 50% below its year-to-date peak, with technical indicators like the 14-day relative strength index (RSI) dropping into deeply oversold territory. Financially, Anavex holds around $131 million in cash with no debt, enough to fund operations for over three years. Analysts maintain a 'Moderate Buy' consensus, with a $22 price target—suggesting a potential ninefold increase over the next 12 months.

The withdrawal of blarcamesine's EU application marks a significant obstacle for Anavex. With the EMA's concerns unresolved, the company must now address regulatory demands before resubmitting. Meanwhile, investors watch closely as the stock's volatility reflects uncertainty about the drug's future.